Abbott Laboratories' revenue and return on invested capital could be more consistent. Read why potential investors will need ...

Abbott today announced the first patient procedures with its investigational transcatheter aortic valve implantation (TAVI) ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Abbott Laboratories (NYSE:ABT) is largely controlled by institutional shareholders who own 78% of the company Institutions' substantial holdings in Abbott Laboratories implies that they have ...

On Thursday, Abbott Laboratories (ABT) stock saw a modest uptick, ending the day at $117.26 which represents a slight increase of $1.33 or 1.15% from the prior close of $115.93. The stock opened at ...

We recently compiled a list of the 8 Magnificent Dividend Growth Stocks to Buy Now. In this article, we are going to take a ...

On Thursday, Abbott Laboratories (ABT) stock saw a decline, ending the day at $115.03 which represents a decrease of $-0.71 or -0.61% from the prior close of $115.74. The stock opened at $115.98 and ...

Three years after the U.S. FDA approval of Abbott Laboratories’ Amplatzer Amulet, results of its investigational device exemption trial failed to notably differentiate Abbott’s left atrial appendage ...

Over half a decade, Abbott Laboratories managed to grow its earnings per share at 12% a year. The EPS growth is more ...

Abbott (NYSE: ABT) today announced the first patient procedures with its investigational transcatheter aortic valve implantation (TAVI) balloon-expandable system for treating symptomatic severe aortic ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target of ...

A review application filed by Abbott Healthcare, alleging that the National Pharmaceutical Pricing Authority (NPPA) used ...